Madrigal Pharma (MDGL) option implied volatility into FDA approval
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Join SI Premium – FREE
Madrigal Pharma (NASDAQ: MDGL) 30-day option implied volatility is at 151; compared to its 52-week range of 49 to 176 into FDA approves Madrigal Pharmaceuticals' Rezdiffra.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron Technology (MU) call put ratio 1.2 calls to 1 put into quarter results
- Americas Silver Corporation (USAS) 14K contracts of August 6 calls trade, share price down 8%
- Ross Stores (ROST) call put ratio 1 call to 1 put as share price down 3%
Create E-mail Alert Related Categories
OptionsRelated Entities
Options, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
